The annual incidence of prostate cancer (PC) in Finland was 4 700 (year 2010). The treatment decision is made together with the patient according to patient characteristics, cancer classification and recurrence risk rate. For local PC, recommended treatment is active surveillance, radical prostatectomy, radiation (+/- hormonal) therapy or hormonal therapy. Metastatic PC patients are treated with hormonal therapy. The aim for castrate resistant metastatic PC patients is to improve quality of life and relieve symptoms. The 5-year survival rate is 93 %. Follow-up is tailored individually. Population based PSA screening is not recommended.
Sirpa Aaltomaa (chair)